Dicyclomine Hydrochloride IP & Hyoscine Butylbromide [7.16]-CMP47 — Monograph & Safety

1. Clinical & Scientific Overview

Dicyclomine Hydrochloride IP & Hyoscine Butylbromide IP (TIP-MED-000317, Reference Code [7.16]-CMP47) is classified under Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Anthranilic Acid (Fenamate) COX-1 / COX-2 Inhibitor & Prostaglandin Receptor Antagonist (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-6-18 & mono-6-20) and DEC-12 (Drotaverine from HTML [12.11]). Anticholinergic antispasmodic comparisons (Dicyclomine contraindicated in infants <6 months; Hyoscine Butylbromide [Buscopan] avoided in glaucoma/BPH).

Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-6-18 & mono-6-20) and DEC-12 (Drotaverine from HTML [12.11]). Anticholinergic antispasmodic comparisons (Dicyclomine contraindicated in infants <6 months; Hyoscine Butylbromide [Buscopan] avoided in glaucoma/BPH).

Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)

Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

4. Therapeutic Indications & Evidence-Supported Uses

Primary dysmenorrhoea (uniquely blocks both prostaglandin synthesis AND uterine myometrial PGE2/PGF2a receptors!), heavy menstrual bleeding (with Tranexamic Acid), acute dental/musculoskeletal pain, refractory pyrexia

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-11 (Option 11A; Inventory CSV mono-6-18 & mono-6-20) and DEC-12 (Drotaverine from HTML [12.11]). Anticholinergic antispasmodic comparisons (Dicyclomine contraindicated in infants <6 months; Hyoscine Butylbromide [Buscopan] avoided in glaucoma/BPH).

Administration & Meal Timing: Take immediately AFTER meals with a full glass of water | Three times daily after Meals for 3–5 Days during menstruation or acute pain

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [7.16].

Metabolism & Biotransformation:
Renal: Contraindicated if eGFR <30–45 mL/min or in dehydrated febrile children. Hepatic: Avoid in active liver disease

Elimination & Renal Adjustment:
Renal: Contraindicated if eGFR <30–45 mL/min or in dehydrated febrile children. Hepatic: Avoid in active liver disease

Hepatic Impairment Considerations:
Renal: Contraindicated if eGFR <30–45 mL/min or in dehydrated febrile children. Hepatic: Avoid in active liver disease

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:

IPC / CDSCO PvPI SAFETY ALERT (2023): Mefenamic acid carries a documented alert for DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)! Contraindicated in peptic ulcer, inflammatory bowel disease, CKD (eGFR <45 mL/min), Heart Failure, post-CABG, and 3rd trimester of pregnancy

Key Clinical Precautions: Renal: Contraindicated if eGFR <30–45 mL/min or in dehydrated febrile children. Hepatic: Avoid in active liver disease

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:

Diarrhoea (very characteristic of fenamates — if diarrhoea occurs, STOP Mefenamic Acid immediately!), dyspepsia, nausea, dizziness
DRESS syndrome (fever, widespread morbilliform rash, facial oedema, lymphadenopathy, eosinophilia, hepatitis/nephritis 2–8 weeks after exposure — PvPI Alert!), haemolytic anaemia, seizures in overdose, GI bleeding, AKI

Serious / Dose-Limiting Adverse Effects:

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

Potentiates Warfarin and DOAC bleeding; increases Lithium and Methotrexate toxicity; Triple Whammy AKI with ACEi/ARB + Diuretic; avoid combining with other NSAIDs

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [7.16].

Pharmacist Patient Counselling Points:

Patient Counselling Checklist: Take after food for a maximum of 5–7 days; stop immediately if you develop diarrhoea, skin rash, fever, or swollen glands (CDSCO PvPI safety alert); never give to a dehydrated child
Meal & Clock Timing Instruction: Take immediately AFTER meals with a full glass of water (Three times daily after Meals for 3–5 Days during menstruation or acute pain)
Missed Dose Protocol: Use PRN during painful menses; do not exceed 7 days
Geriatric Dispensing Pearl: Avoid in older adults due to high GI diarrhoea/ulcer and renal toxicity risk

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablets: 250 mg, 500 mg; Paediatric Suspension: 100 mg/5 mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

13. Related Reference Monographs, Educational Guides & Visual Concept

💊 Related Pharmacological / Category Profiles

[7.12] Methotrexate (Low-Dose Weekly Immunomodulator / DMARD Regimen) — Folate Antimetabolite (Dihydrofolate Reductase & AICAR Transformy
[7.13] Thiocolchicoside, Tolperisone Hydrochloride & Chlorzoxazone (Spinal & Central Muscle Relaxants) — Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agent
[7.14] Piroxicam & Meloxicam — Long-Half-Life Oxicam NSAIDs — Non-Selective & Preferential COX-2
[7.15] Ketorolac Tromethamine — Potent Pyrrolizine Carboxylic Acid Non-Selective COX Inhibitor An

📚 Related Knowledge Hub Educational Articles

Receptor Pharmacodynamics & Mechanism of Action Illustration

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback